Thursday, 4 September 2025
  
Login

Australia's most trusted
source of pharma news

Thursday, 04 September 2025
News

Big drug deferrals mark PBAC meet

Posted 1 September 2025 AM

BMS’ broad access proposal for Opdivo and Yervoy plus two potential PBS debutants are among six submissions on the PBAC’s September intracycle meeting.

The PBAC deferred BMS’ multi-indication listing proposal of Opdivo and Yervoy in unresectable advanced and metastatic cancer at the recent July meeting – the same meeting that it knocked back MSD's similar proposal for Keytruda.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (13)

Clinical & Medical, R&D (13)

Regulatory, Pharmacovigilance & QA (6)

Other (14)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.